Interesting the CEO says "we are confident that our clinical study program provides the foundations to regain coverage from any possible non-coverage determination."
- Forums
- ASX - By Stock
- PEB
- Ann: Quarterly Update - Cxbladder Test Volumes Steady in Q4 24
Ann: Quarterly Update - Cxbladder Test Volumes Steady in Q4 24, page-2
Featured News
Add PEB (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.33M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 600 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28 | 0.084 |
1 | 3000 | 0.080 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 600 | 1 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
Last trade - 16.12pm 27/06/2024 (20 minute delay) ? |
Featured News
PEB (ASX) Chart |
Day chart unavailable